← All trials
NCT03542461
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 25, 2017
- Primary completion
- Sep 30, 2022
- Completion date
- Sep 30, 2022
- First posted
- —
- Last posted
- —
- Enrollment
- 388
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Gruppo Oncologico Italiano di Ricerca ClinicaLead sponsor
- Mipharm SpACollaborator
- Bioikos Ambiente SrlCollaborator
- University of BristolCollaborator
- Istituto Toscano TumoriCollaborator
- University of BolognaOverall official - principal investigator
- University of ParmaStudy chair
- Temas srlCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.